<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03558087</url>
  </required_header>
  <id_info>
    <org_study_id>HCRN GU16-257</org_study_id>
    <nct_id>NCT03558087</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing</brief_title>
  <official_title>Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthew Galsky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 trial seeking to define the safety and activity of gemcitabine, cisplatin,&#xD;
      plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to&#xD;
      define the role of clinical complete response in predicting benefit in patients opting to&#xD;
      avoid cystectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 13, 2018</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the clinical complete response rate (cT0 or cTa) with gemcitabine, cisplatin, plus nivolumab</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical complete response rate will be defined as cT0 or cTa disease after gemcitabine, cisplatin, plus nivolumab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the ability of clinical complete response (cT0 or cTa) to predict benefit from treatment.</measure>
    <time_frame>24 months</time_frame>
    <description>Benefit will be defined as a pathologic complete response (&lt;pT1) in patients undergoing cystectomy and 2 year metastasis-free in patients pursuing surveillance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Assess adverse events according to the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder intact overall survival</measure>
    <time_frame>24 Months</time_frame>
    <description>Bladder-intact overall survival is defined as the time from initiation of treatment until death or cystectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Recurrence-free survival is defined as the time from initiation of treatment to death or recurrence, depending on which occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response rate in patients undergoing cystectomy</measure>
    <time_frame>24 Months</time_frame>
    <description>Pathologic complete response rate in patients undergoing radical cystectomy is defined as the proportion of patients with &lt;pT1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the association between a prespecified panel of genomic biomarkers and benefit from treatment in patients achieving a clinical complete response.</measure>
    <time_frame>24 months</time_frame>
    <description>Benefit will be defined as a pathologic complete response (p&lt;T1) in patients undergoing cystectomy and 2 years metastasis-free in patients pursuing surveillance</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine, Cisplatin and Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination Therapy: Nivolumab 360mg IV, Gemcitabine 100mg/m^2 IV ,Cisplatin 70mg/m^2 IV for four 21-day cycles. At restaging, subjects with cT0 or cTa status may undergo cystectomy or continue maintenance Nivolumab 240mg IV for up to 8 14-day cycles. Subjects with &gt; cTa status will undergo cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).</description>
    <arm_group_label>Gemcitabine, Cisplatin and Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four 21-day cycles.</description>
    <arm_group_label>Gemcitabine, Cisplatin and Nivolumab</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 70mg^m2 will be administered on Day 1 for four 21-day cycles.</description>
    <arm_group_label>Gemcitabine, Cisplatin and Nivolumab</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG Performance Status of ≤ 1 within 28 days prior to registration.&#xD;
&#xD;
          -  Histological evidence of clinically localized muscle-invasive urothelial cancer of the&#xD;
             bladder (i.e., ct2-4n0m0). candidate for cystectomy as per treating physician.&#xD;
&#xD;
          -  Demonstrate adequate organ function per listed criteria:&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC): ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin (Hgb): ≥ 9 g/dL&#xD;
&#xD;
          -  Platelets: ≥ 100 x 10^9/L&#xD;
&#xD;
          -  Calculated creatinine clearance: Creatinine ≤ 1.5 or creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Bilirubin: ≤ 1.5 × upper limit of normal (ULN) (except subjects with Gilbert Syndrome,&#xD;
             who can have total bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) : ≤ 3 × ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) : ≤ 3 × ULN&#xD;
&#xD;
          -  All subjects must have adequate archival tissue identified at screening (i.e., at&#xD;
             least 15 unstained slides or paraffin block). Subjects without available archival&#xD;
             tissue must be discussed with the sponsor-investigator.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy within 7&#xD;
             days prior to C1D1. NOTE: &quot;Women of childbearing potential&quot; is defined as any female&#xD;
             who has experienced menarche and who has not undergone surgical sterilization&#xD;
             (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is&#xD;
             defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of&#xD;
             other biological or physiological causes. In addition, women under the age of 62 must&#xD;
             have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.&#xD;
&#xD;
        NOTE: Women of childbearing potential (WOCBP) receiving nivolumab must be willing to&#xD;
        abstain from heterosexual activity or to use 2 forms of effective methods of contraception&#xD;
        from the time of informed consent to 5 months after the last dose of investigational&#xD;
        product.. The two contraception methods can be comprised of two barrier methods, or a&#xD;
        barrier method plus a hormonal method. Men will not be required to use contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with systemic chemotherapy for muscle-invasive urothelial cancer of&#xD;
             the bladder&#xD;
&#xD;
          -  Active infection requiring systemic therapy&#xD;
&#xD;
          -  Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the&#xD;
             mother is being treated on study).&#xD;
&#xD;
          -  Any serious or uncontrolled medical disorder that, in the opinion of the investigator,&#xD;
             may increase the risk associated with study participation or study drug&#xD;
             administration, impair the ability of the subject to receive protocol therapy, or&#xD;
             interfere with the interpretation of study results.&#xD;
&#xD;
          -  Prior malignancy active within the previous 3 years except for locally curable cancers&#xD;
             that have been apparently cured.&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,&#xD;
             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only&#xD;
             requiring hormone replacement, psoriasis not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll.&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration. Inhaled or topical steroids and adrenal replacement&#xD;
             doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of active&#xD;
             autoimmune disease.&#xD;
&#xD;
          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or&#xD;
             any other antibody or drug specifically targeting T-cell co-stimulation or immune&#xD;
             checkpoint pathways.&#xD;
&#xD;
          -  Grade ≥ 2 neuropathy (NCI CTCAE version 4).&#xD;
&#xD;
          -  Prior radiation therapy for bladder cancer&#xD;
&#xD;
          -  Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus&#xD;
             ribonucleic acid (RNA) or hepatitis C antibody (HCV antibody) indicating acute or&#xD;
             chronic infection.&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS).&#xD;
&#xD;
          -  Evidence of interstitial lung disease or active, non-infectious pneumonitis.&#xD;
&#xD;
          -  Solid organ or allogeneic stem cell transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Galsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerity of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Medicine Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Matthew Galsky</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>muscle-invasive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

